This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Neoplasms  • Alert me on articles by topic

Patients Providing the Power

Stuart R. Lessin, MD

Arch Dermatol. 2007;143(7):916-918.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Cutaneous T-cell lymphoma (CTCL) is a term currently used for the classification of a variety of subtypes of T-cell lymphoma that primarily affect the skin.¹ The initial use of the term CTCL, however, was coined by Edelson² to describe the most common variant of CTCL, mycosis fungoides (MF), and its leukemic variant, Sézary syndrome (SS). In this editorial, the term CTCL will specifically refer to MF and SS, which is the subject of the current epidemiologic study of Criscione and Weinstock³ presented in this issue of the Archives. Because this study was funded by a grant from the Cutaneous Lymphoma Foundation (http://www.clfoundation.org), it represents a unique paradigm in clinical research: a population-based study made possible by advocates for the patient population under investigation.

For 200 years, since Alibert's initial description of patients in 1806,⁴ the etiology of CTCL has remained . . . [Full Text of this Article]

AUTHOR INFORMATION

RELATED ARTICLE

Incidence of Cutaneous T-Cell Lymphoma in the United States, 1973-2002
Vincent D. Criscione and Martin A. Weinstock
Arch Dermatol. 2007;143(7):854-859.
ABSTRACT | FULL TEXT